Barclays
BLTE

Barclays’s Belite Bio BLTE Stock Holding History

Barclays’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Hold
6,822
– – ﹤0.01% 2763
2026
Q1 		$1.09M Buy
6,822
+2,646
+63% +$445K ﹤0.01% 2709
2025
Q4 		$668K Buy
+4,176
New +$495K ﹤0.01% 3690
2022
Q4 		– Sell
-6,661
Closed -$223K – 5272
2022
Q3 		$223K Buy
+6,661
New +$230K ﹤0.01% 3136

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's BLTE Position: Q2 2026 in Review

Barclays held its Belite Bio (BLTE) position steady in Q2 2026 at 6,822 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2763.

Barclays first reported a position in BLTE in Q3 2022 and has held it in 4 quarters since. The position peaked at $1.09M in Q1 2026. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Barclays held 6,822 shares of Belite Bio worth $1.05M as of Q2 2026.
  • Barclays left its Belite Bio share count unchanged in Q2 2026.
  • Belite Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2763 holding.
  • Barclays first reported a position in Belite Bio in Q3 2022 and has held it in 4 quarters since.
  • Barclays's Belite Bio position peaked at $1.09M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.